-
Block T M, Lu X, Mehta A S, et al. 1998. Treatment of chronic hepadnavirus infection in a woodchuck animal model with an inhibitor of protein folding and trafficking. Nat Med, 4:610-614.
doi: 10.1038/nm0598-610
-
Chotiyaputta W, Lok A. 2009. hepatitis B virus variants. Nat Rev Gastroenterol Hepatol, 6: 453-462.
doi: 10.1038/nrgastro.2009.107
-
Delaney W E 4th, Edwards R, Colledge D, et al. 2002. Phenylpropenamide derivatives AT-61 and AT-130 inhibit replication of wild-type and lamivudine-resistant strains of hepatitis B virus in vitro. Antimicrob Agents Chemother, 46: 3057-3060.
doi: 10.1128/AAC.46.9.3057-3060.2002
-
Deng Q, Zhai J W, Michel M L, et al. 2007. Identification and characterization of peptides that interact with hepatitis B virus via the putative receptor binding site. J Virol, 81: 4244-4254.
doi: 10.1128/JVI.01270-06
-
Deres K, Schroder C H, Paessens A, et al. 2003. Inhibition of hepatitis B virus replication by drug-induced depletion of nucleocapsids. Science, 299: 893-896.
doi: 10.1126/science.1077215
-
Dienstag J L. 2008. Hepatitis B virus infection. N Engl J Med, 359:1486-1500.
doi: 10.1056/NEJMra0801644
-
Ganem D, Prince A M. 2004. Hepatitis B virus infection-natural history and clinical consequences. N Engl J Med, 350:1118-1129.
doi: 10.1056/NEJMra031087
-
Glebe D, Urban S, Knoop E V, et al. 2005. Mapping of the hepatitis B virus attachment site by use of infection-inhibiting preS1 lipopeptides and tupaia hepatocytes. Gastroenterology, 129: 234-245.
doi: 10.1053/j.gastro.2005.03.090
-
Gripon P, Cannie I, Urban S. 2005. Efficient inhibition of hepatitis B virus infection by acylated peptides derived from the large viral surface protein. J Virol, 79: 1613-1622.
doi: 10.1128/JVI.79.3.1613-1622.2005
-
King R W, Ladner S K, Miller T J, et al. 1998. Inhibition of human hepatitis B virus replication by AT-61, a phenylpropenamide derivative, alone and in combination with (-)β-L-2', 3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother, 42: 3179-3186.
-
Lampertico P. Viganò M, Manenti E, et al. 2007. Low resistance to adefovir combined with lamivudine: a 3-year study of 145 lamivudine-resistant hepatitis B patients. Gastroenterology, 133: 1445-1451.
doi: 10.1053/j.gastro.2007.08.079
-
Lazar C, Durantel D, Macovei A, et al. 2007. Treatment of hepatitis B virus-infected cells with alpha-glucosidase inhibitors results in production of virions with altered molecular composition and infectivity. Antiviral Res, 76: 30-37.
doi: 10.1016/j.antiviral.2007.04.004
-
Lucifora J, Durantel D, Testoni B, et al. 2010. Control of hepatitis B virus replication by innate response of HepaRG cells. Hepatology, 51: 63-72.
doi: 10.1002/hep.23230
-
Mancini-Bourgine M, Fontaine H, Bréchot C, et al. 2006. Immunogenicity of a hepatitis B DNA vaccine administered to chronic HBV carriers. Vaccine, 24: 4482-4489.
doi: 10.1016/j.vaccine.2005.08.013
-
Mehta A, Carrouée S, Conyers B, et al. 2001. Inhibition of hepatitis B virus DNA replication by imino sugars without the inhibition of the DNA polymerase: therapeutic implications. Hepatology, 33: 1488-1495.
doi: 10.1053/jhep.2001.25103
-
Perrillo R. 2009. Benefits and risks of interferon therapy for hepatitis B. Hepatology, 49: S103-111.
doi: 10.1002/hep.v49.5s
-
Petersen J, Dandri M, Mier W, et al. 2008. Prevention of hepatitis B virus infection in vivo by entry inhibitors derived from the large envelope protein. Nat Biotechnol, 26: 335-341.
doi: 10.1038/nbt1389
-
Rehermann B, Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nature Rev Immunol, 5: 215-229.
doi: 10.1038/nri1573
-
Riordan S M, Skinner N, Kurtovic J, et al. 2006. Reduced expression of toll-like receptor 2 on peripheral monocytes in patients with chronic hepatitis B. Clin Vaccine Immunol, 13: 972-974.
doi: 10.1128/CVI.00396-05
-
Seeger C, Mason W S. 2005. Hepatitis B virus biology. Microbiol Mol Biol Rev, 2000, 64: 51-68.
-
Shepard C W, Simard E P, Finelli L, et al. 2006. Hepatitis B virus infection: epidemiology and vaccination. Epidemiol Rev, 28: 112-125.
doi: 10.1093/epirev/mxj009
-
Thompson A J, Colledge D, Rodgers S, et al. 2009. Stimulation of the interleukin-1 receptor and Toll-like receptor 2 inhibits hepatitis B virus replication in hepatoma cell lines in vitro. Antivir Ther, 14: 797-808.
doi: 10.3851/IMP1294
-
Vincent I E, Lucifora J, Durantel D, et al. 2009. Inhibitory effect of the combination of CpG-induced cytokines with lamivudine against hepatitis B virus replication in vitro. Antivir Ther, 14: 131-135.
-
Weber O, Schlemmer K H, Hartmann E, et al. 2002. Inhibition of human hepatitis B virus (HBV) by a novel non-nucleosidic compound in a transgenic mouse model. Antiviral Res, 54: 69-78.
doi: 10.1016/S0166-3542(01)00216-9
-
Xu D Z, Zhao K, Guo L M, et al. 2008. A randomized controlled phase Ⅱb trial of antigen-antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS One, 3: e2565.
-
Yao X, Zheng B, Zhou J, et al. 2007. Therapeutic effect of hepatitis B surface antigen-antibody complex is associated with cytolytic and non-cytolytic immune responses in hepatitis B patients. Vaccine, 25: 1771-1779.
doi: 10.1016/j.vaccine.2006.11.019
-
Zimmerman K A, Fischer K P, Joyce M A, et al. 2008. Zinc finger proteins designed to specifically target duck hepatitis B virus covalently closed circular DNA inhibit viral transcription in tissue culture. J Virol, 82: 8013-8021.
doi: 10.1128/JVI.00366-08